Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Heidelberg, Germany, March 23, 2017 - Affimed N.V. (Nasdaq: AFMD) today announced that on March 30, 2017, the Company will release its financial results for the quarter and year ended December 31, 2016. The Company's management team will host a conference call to discuss the Company's financial results and recent corporate developments on Thursday, March 30, 2017 at 8:30 a.m. ET. The call can be accessed by dialing one of the numbers listed below five minutes prior to the start of the call and providing the confirmation code 9811704.
| Local - Amsterdam, the Netherlands: | +31 (0) 20 721 9158 |
| Local - Copenhagen, Denmark: | +45 32 71 16 60 |
| Local - Frankfurt, Germany: | +49 (0) 69 2222 10626 |
| Local - Geneva, Switzerland: | +41 (0) 22 417 7109 |
| Local - London, U.K.: | +44 (0) 20 3427 1911 |
| Local - New York City, U.S.A.: | +1 646 254 3361 |
| Local - Paris, France: | +33 (0) 1 76 77 22 22 |
An audio webcast of the conference call can be accessed in the "Events" section on the "Investors & Media" page of the Affimed website at http://www.affimed.com/events.php. A replay of the webcast will be available on Affimed's website shortly after the conclusion of the call and will be archived on the Affimed website for 30 days following the call.
About Affimed N.V.
Affimed (Nasdaq: AFMD) engineers targeted immunotherapies, seeking to cure patients by harnessing the power of innate and adaptive immunity (NK- and T-cells). We are developing single and combination therapies to treat cancers and other life-threatening diseases. For more information, please visit www.affimed.com.
IR Contact:
Caroline Stewart, Head IR
Phone: +1 347394 6793
E-Mail: [email protected] or [email protected]
Media Contact:
Anca Alexandru, Head of Communications, EU IR
Phone: +49 6221 64793341
E-Mail: [email protected]
